Unicycive Therapeutics (NASDAQ:UNCY) vs. Fortress Biotech (NASDAQ:FBIO) Financial Review

Fortress Biotech (NASDAQ:FBIO – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Profitability

This table compares Fortress Biotech and Unicycive Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fortress Biotech 143.04% 61.84% 35.15%
Unicycive Therapeutics N/A -83.34% -56.69%

Valuation & Earnings

This table compares Fortress Biotech and Unicycive Therapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fortress Biotech $63.26 million 1.01 $6.82 million $2.30 0.83
Unicycive Therapeutics $680,000.00 143.75 -$26.56 million ($1.67) -2.01

Fortress Biotech has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Fortress Biotech and Unicycive Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortress Biotech 1 1 2 0 2.25
Unicycive Therapeutics 1 1 5 0 2.57

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 794.74%. Unicycive Therapeutics has a consensus price target of $18.25, suggesting a potential upside of 444.78%. Given Fortress Biotech’s higher probable upside, research analysts plainly believe Fortress Biotech is more favorable than Unicycive Therapeutics.

Institutional and Insider Ownership

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Fortress Biotech has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.

Summary

Fortress Biotech beats Unicycive Therapeutics on 10 of the 14 factors compared between the two stocks.

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.